Current Announcements
EAI141, Evaluating use of FLT PET/CT to Monitor Treatment Response in AML, Activated

EAI141 - Early Assessment of Treatment Response in AML using FLT PET/CT Imaging - is now open for subject recruitment. This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia (AML).

 read more ...

NCI-MATCH / EAY131 Reactivated
National Cancer Institute-Molecular Analysis for Therapy Choice, known as NCI-MATCH or study EAY131, is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. read more ...

Slideshow image
Accrin_Container_Arrow DATA CENTER LOGIN

The data center supports around the clock web-based patient registration.  Data Center Login

Accrin_Container_Arrow LINKS

Contact Us

TRIAD Pre-Installation Checklist
A document outlining TRIADTM installation procedures and requirements

ACRIN Publications 
Policy document and submission forms for publication review

ACRIN Biostatistics Center 
A link to the Web site of the Center for Statistical Sciences at Brown University


 ACRIN and cancer imaging research have experienced groundbreaking developments within the last decade. We are grateful to have been instrumental in facilitating clinical research that is making a difference in the lives of cancer patients. Several ACRIN trials are now among the highest profile clinical trials in NCI’s portfolio and a majority of trials involve collaboration with therapy cooperative groups or industries.

Looking to future research plans, ACRIN anticipates developing even more precise quantitative approaches to diagnosis and image-guided therapy. Specific objectives involve surveillance of high-risk populations, administration of targeted therapies, and use of biomarkers to evaluate therapeutic response. The new Experimental Imaging Sciences Committee is charged with exploring new modalities, new uses for established modalities, and new equipment. I personally take great pride in the opportunity afforded me to work with so many talented imagers from across the country.

I invite you to explore our Web site to learn more about:

  • How to participate in ACRIN trials and research activities
  • The diversity of ACRIN’s research and related research strategies
  • ACRIN’s extensive support for conducting multi-center trials.

We look forward to playing an active role in the innovations on the horizon for the cancer imaging research community.

Mitchell Schnall, MD, PhD
Network Chair



As a result of recent changes in HIPAA and PCI compliance regulations legacy browsers that do not meet the minimum requirements for transmitting sensitive data are not supported. Only the following browsers are currently supported: